Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...
Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies are expected to go public amid a ...
Nvidia and Eli Lilly's AI tie-up shows drug discovery emerging as a new ETF growth theme across semiconductors and health care.
The green shoots suggesting a comeback was in sight for biotech stocks last year have mostly grown into proverbial flowering plants—but one company’s precipitous year-over-year decline in market ...
Inhibrx develops next-generation protein therapeutics as nasdaq futures shape broader biotechnology discussions.
Business and Financial Times on MSN
Financial Security (FinSec) series with Dr Philip Takyi: Beyond the surface: How growing systemic risks and shadow-bank trends are reshaping US investment funds—from growth ...
Most people invest without ever thinking about how the system behind their money actually works. When you buy into a mutual fund, ETF, or closed-end fund, you are relying on investment companies to ...
ARK Invest bought $15.88M in GeneDx stock and sold $12.7M in Meta shares. Cathie Wood shifts portfolio from tech giants to ...
Asianet Newsable on MSN
Cathie Wood’s ARK made just one buy last session — and it’s a biotech stock up nearly 30% YTD
On Thursday, ARK bought a total of 56,769 shares of Intellia, with 48,178 shares purchased by its ARKK ETF and 8,591 shares ...
Another significant acquisition was 262,769 shares of Personalisis Inc (NASDAQ:PSNL) through the ARKG ETF, valued at $2,251,930. This continues ARK’s trend of increasing its stake in Personalisis, ...
There were 55 new listings on the Malaysian bourse last year (excluding the five listings on the LEAP Market) — surpassing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback